Ache Itches to Go Public
Amid growing investor appetite for an IPO from the still untapped Brazil pharmaceutical industry, Ache, one of the country’s leading drug companies, is heard in advanced talks to go public. Brazil’s largest investors, including portfolio managers at Itau-Unibanco Asset Management (IUAM) and Bradesco Asset Management (BRAM), say a substantial, well-run company from that sector would draw significant...
Already have an account?
Subscribe now for unlimited access to all current and archive news, data and market analysis.
Take a free two-week trial now for the latest news, data and market analysis.